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Background. Activating somatic mutations in epidermal growth factor receptor (EGFR) confer unique biologic features to non-
small cell lung cancer (NSCLC) cells, but the transcriptional mediators of EGFR in this subgroup of NSCLC have not been fully
elucidated. Methodology/Principal Findings. Here we used genetic and pharmacologic approaches to elucidate the
transcriptomes of NSCLC cell lines. We transcriptionally profiled a panel of EGFR-mutant and -wild-type NSCLC cell lines
cultured in the presence or absence of an EGFR tyrosine kinase inhibitor. Hierarchical analysis revealed that the cell lines
segregated on the basis of EGFR mutational status (mutant versus wild-type), and expression signatures were identified by
supervised analysis that distinguished the cell lines based on mutational status (wild-type versus mutant) and type of mutation
(L858R versus D746-750). Using an EGFR mutation-specific expression signature as a probe, we mined the gene expression
profiles of two independent cohorts of NSCLC patients and found the signature in a subset. EGFR tyrosine kinase inhibitor
treatment regulated the expression of multiple genes, and pharmacologic inhibition of the protein products of two of them
(PTGS2 and EphA2) inhibited anchorage-independent growth in EGFR-mutant NSCLC cells. Conclusions/Significance. We
have elucidated genes not previously associated with EGFR-mutant NSCLC, two of which enhanced the clonogenicity of these
cells, distinguishing these mediators from others previously shown to maintain cell survival. These findings have potential
clinical relevance given the availability of pharmacologic tools to inhibit the protein products of these genes.
Citation: Choi K, Creighton CJ, Stivers D, Fujimoto N, Kurie JM (2007) Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating
EGFR Somatic Mutations. PLoS ONE 2(11): e1226. doi:10.1371/journal.pone.0001226
INTRODUCTION
Treatment with epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) leads to rapid and sustained tumor
shrinkage in a subset of patients with non–small cell lung cancer
(NSCLC) [1–3]. The tumor cells in these patients have somatic
mutations in the EGFR kinase domain that constitutively activate
EGFR [1–3]. The activating mutations identified thus far cluster
in the region that encodes the kinase domain (exons 18–21) and
are most frequently either D746–750 deletion or L858R point
mutations [1–3]. Mouse models constructed to investigate the
oncogenicity of mutant EGFR develop invasive lung adenocarci-
nomas that regress after treatment with EGFR TKIs [4;5].
Immortalized human bronchial epithelial cells acquire malignant
properties after transfection with mutant EGFR [6]. Treatment
with EGFR TKIs induces apoptosis of these EGFR-transfected
cells and NSCLC cells with somatic mutations in EGFR [7;8].
Thus, evidence from human, murine, and cellular models
indicates that mutant EGFR is oncogenic and confers dependence
on EGFR for NSCLC cell survival.
The potency of mutant EGFR as an oncogene is supported by
evidence that its biochemical properties differ sharply from those
of wild-type EGFR. The EGFR kinase domain is constitutively
activated by the somatic mutations, and it displays enhanced
binding and sensitivity to EGFR TKIs [9–11]. EGFR-mutant
NSCLC cells typically express high levels of EGFR and its dimeric
partners ErbB2 and ErbB3 and multiple ErbB ligands, all of which
potentiate EGFR-dependent signaling [8]. Multiple signaling
pathways are constitutively activated in these cells, some of which
have been shown to promote cell survival. For example, EGFR
forms a heterodimeric complex with ErbB3, which binds to and
directly activates phosphatidylinositol 3-kinase and maintains cell
survival through AKT-dependent mechanisms [12]. Other pro-
survival signals are mediated through Src family kinases, which are
constitutively activated in EGFR-mutant NSCLC cells [13;14].
In contrast to the advances made in elucidating mediators of cell
survival, less progress has been made in understanding the
mechanisms by which mutant EGFR confers other neoplastic
properties, such as the ability to migrate, invade, proliferate in an
anchorage-independent manner, and promote angiogenesis. Here
we sought to identify those mediators by interrogating the
transcriptomes of a panel of NSCLC cell lines that have been
characterized for the presence of EGFR mutations. We found
a transcriptional profile of EGFR-mutant NSCLC cells that
included genes not previously been known to be EGFR-
dependent. Although the range of cellular functions attributed to
these genes is broad, many of them are linked through known or
predicted protein interaction networks. In conclusion, the
transcriptional profile identified in EGFR-mutant NSCLC cells
has informed us about biologic processes and potential therapeutic
targets that could be effective in patients with this disease.
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Transcriptional Analysis of NSCLC Cell Lines
We used a panel of eight NSCLC cell lines (Table 1) that had been
characterized for the presence or absence of somatic EGFR mutations
(five cell lines with such mutations and three without) and Ras
mutations (two cell lines with such mutations and six without). Of the
five EGFR-mutant cell lines, three had exon 19 deletion mutations
(D746–750)(HCC827,HCC2279,H4006),onehadanexon21point
mutation (L858R) (H3255), and one had L858R in combination with
the T790M gatekeeper mutation that confers resistance to EGFR
TKIs (H1975). Of the three EGFR-wild-type cell lines, one had
a somatic mutation in N-ras (H1299), and one had a K-ras mutation
(H460). RNA was extracted and prepared from cells after they had
been cultured for 2 h at 70% confluence in the presenceor absence of
the EGFR TKI gefitinib (1.0 mM). This duration of TKI treatment
was chosen to identify the earliest transcriptional events induced by
EGFR inhibition and to minimize the detection of gene expression
changes due to apoptosis.The RNA wassubjected to Affymetrixgene
expression profiling, and the profiles were examined for differences in
gene expression at baseline and after TKI treatment.
We first examined EGFR mutational status as a classifier of the
transcriptional profiles. Hierarchical analysis revealed clustering of
the cell lines based on mutational status; the EGFR-mutant cells
lines clearly segregated from the -wild-type cell lines (Fig. 1).
However, there was no clear separation between the two types of
mutations (L858R versus D746–750) (Fig. 1). By supervised
analysis using specific criteria (at least a 2.0-fold increase or
a 50% decrease in EGFR-mutant cell lines relative to that of wild-
type, P,0.05), 194 unique genes were identified that distinguished
the EGFR-mutant cell lines from the –wild-type cell lines. These
genes are listed in File S1 and illustrated in a clustered heat map in
Fig. 2A. We examined 29 of the 194 genes by quantitative PCR
and validated that 19 (68%) of them were differentially expressed
between EGFR-mutant and –wild-type cell lines (File S2).
Identification of the Mutant EGFR Signature in
Cohorts of Patients with NSCLC
We next queried publicly available gene expression databases of
tumor biopsy samples derived from two independent cohorts of
patients with NSCLC from the United States (15, 16) to determine
whether a subset of tumors expressed this genetic signature. Of the
194 genes, 102 (53%) were represented on the profiling platform
used in the Harvard cohort, and 65 (34%) were represented in the
Michigan cohort. Based on a heat map representation of their
gene expression patterns, the human lung tumors were heteroge-
neous in their expression patterns; however, a subset of tumors (9
of 84 [11%] in the Harvard cohort and 10 of 86 [12%] in the
Michigan cohort) exhibited an expression pattern similar to that of
the EGFR-mutant NSCLC gene signature (Fig. 2B).
To determine whether the similarities observed by heat map
analysis reached statistical significance, parameters were created
that defined similarity as a positive Pearson’s correlation of
P,0.05 (two-sided) between the mutant EGFR signature pattern
and the gene expression values of the tumor, taking into account
both the over- and under-expressed genes in the signature. By this
definition, tumors manifesting this signature would recapitulate
the patterns of over-and under-expression observed in the EGFR-
mutant cell lines. The incidence of tumors manifesting the
signature was statistically significant (P,0.01 for each cohort)
based on simulations using 100 randomly selected gene signatures
generated from each of the cohorts (Fig. 2C).
Although the EGFR mutational status of tumors from these
patient cohorts has, to our knowledge, not been reported, K-ras
(codons 12, 13, or 61) is known to be mutated in 29% and 45% of
the tumors from the Harvard and Michigan cohorts, respectively
[15;16]. Somatic mutations in EGFR and K-ras are mutually
exclusive in NSCLC [17], which has led investigators to
hypothesize that these events are genetically redundant and that
a change in both genes does not confer a further advantage when
these events occur together in the same cell [17]. We postulated
that, if these somatic events are genetically redundant, then having
the K-ras mutation will confer the mutant EGFR transcriptional
profile. Consistent with this idea, we noted that K-ras mutational
status correlated, albeit weakly, with the mutant EGFR gene
signature (Fig. 2B, P=0.07 and P=0.04 in the Harvard and
Michigan cohorts, respectively, by Wilcoxon rank-sum tests of the
cohort profiles ordered by average expression of genes that were
increased in EGFR-mutant cell lines).
Table 1. Characteristics of NSCLC Cell Lines
......................................................................
Cell Line EGFR Gefitinib IC50 Ras
H1299 WT 38.0 mM N-RasQ61K
H1819 WT 4.7 mMW T
H460 WT 8.0 mM K-RasQ61H
H1975 L858R, T790M 1.9 mMW T
HCC2279 D746–750 5.0 mMW T
H3255 L858R 9.0 nM WT
H4006 D746–750 30.0 nM WT
HCC827 D746–750 16.0 nM WT
Abbreviations: WT, wild-type; IC50 , 50% inhibitory concentration Gefitinib IC50
values have been reported (Fujimoto et al., 2005).
doi:10.1371/journal.pone.0001226.t001
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Figure 1. Hierarchical analysis of gene expression profiles in eight
NSCLC cell lines. Dendrogram illustrating the relatedness of expression
profiles from cell lines treated with (+) or without (2) gefitinib. The
presence or absence of EGFR somatic mutations and the type of
mutations, including L858R point mutation (P) or D746–750 deletion
mutation (D), are indicated. WT, wild-type.
doi:10.1371/journal.pone.0001226.g001
NSCLC Transcriptome
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Dependent Genes
To investigate whether any of the genes in the 194-gene signature
were regulated in an EGFR-dependent manner, we queried
a publicly available database of MCF-7 breast cancer cells that
had been stably transfected with constitutively active kinases (Raf1,
MEK1, ErbB2) or with wild-type EGFR, which was activated by
short-term EGF treatment [18]. We investigated the overlap
between the gene signatures from EGFR-transfected MCF-7 cells
and EGFR-mutant NSCLC cells. Of the 194 genes in the mutant
EGFR signature, 139 (72%) were represented on the profiling
platform for the MCF-7 cell transfectants (11079 genes in all were
represented in both the MCF-7 and NSCLC datasets). Analysis of
these 139 genes revealed that subsets of the genes that were
increased in MCF-7 cells because of MEK, Raf1, or EGFR
transfection overlapped with those in the mutant EGFR expression
signature in NSCLC cells (Fig. 2D).
Of the 119 genes that were both represented in the MCF-7
dataset and increased in EGFR-mutant NSCLC cells, 44 (31%)
were increased with P,0.05 in EGFR-transfected MCF-7 cells,
which represented a highly significant overlap (P,1E–12, one-
sided Fisher’s exact test, Fig. 2E). By chance, 14 of the 119 genes
would be expected to overlap, indicating that the amount of
overlap we observed exceeded what would be expected if the
EGFR-transfected MCF-7 cells and EGFR-mutant NSCLC cells
nothing biologically in common with each other. When we used
a more stringent cut point of P,0.01 instead of P,0.05 to define
genes that were increased in EGFR-transfected MCF-7 cells (576
genes in all), 28 overlapped with the mutant EGFR NSCLC
signature (chance expected of seven genes, P,1E–10, one-sided
Fisher’s exact test). We concluded that, based on its commonalities
Figure 2. Identification of a mutant EGFR gene expression profile. (A) A 194-gene signature that distinguishes EGFR-wild-type (WT) from -mutant
NSCLC cell lines (treated with [+] or without [2] gefitinib) is aligned with the expression profiles from (B) the Michigan cohort (86 patients) and the
Harvard cohort (84 patients) and (D) MCF-7 cells transfected with the indicated genes. A list of the genes that overlapped in all three data sets is
indicated on the far right. (C) Numbers of patients in the Michigan and Harvard cohorts manifesting the mutant EGFR expression patterns (P,0.05,
Pearson’s correlation), along with the number manifesting a randomly generated pattern (SD based on 100 simulations). (E) Venn diagram illustrating
the overlap between signatures from the EGFR-mutant NSCLC cells and EGFR-transfected MCF-7 cells.
doi:10.1371/journal.pone.0001226.g002
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signature from EGFR-mutant NSCLC cells was enriched for
genes transcriptionally up-regulated by EGFR.
Identification of PTGS2 as a gene required for
anchorage-independent growth
The genes that were differentially expressed in EGFR-mutant
NSCLC cell lines fell into a broad range of functional classes
(categorized in the Gene Ontology Molecular Functions, www.
geneontology.org) (Files S3 and S4). The categories with highest
representation were signal transduction, metabolism, immune
response, ion transport, and cell cycle and proliferation. Genes in
these categories that were highly expressed included those encoding
ErbB ligands (TGFA, AREG,a n dEREG), cyclooxygenase-2 (PTGS2),
a ligand for the CX3CR1 chemokine receptor (CX3CL1),i n -
tracellular and transmembrane kinases (TRIB2, MET, MYLK,
STK39, ACVR1, TAOK3, and IFIH1), protein phosphatases (PTPN22,
DUSP10, PPAP2B, PTPRR, and PTPRE), a lipid phosphatase
(SGPP2), adhesion molecules (CEACAM6, ITGAV, PCDH7, and
THBS1), and calcium ion-binding proteins (S100A14 and S100A16).
To examine whether these differentially expressed genes, which
have disparate biologic functions, were part of one or more signal
transduction networks, we analyzed their positions within known or
predicted global protein interaction networks (interactomes) using
the HiMAP software program (http://www.himap.org/index.jsp).
Interactomes identified by this approach are organized into a series
of modular structures characterized by centrally-located nodes
(called hubs)that havemultiple connections with otherproteins [19].
Although this approach is purely exploratory and carries no
statistical weight, findings in yeast show that centrality in a protein
interactome predicts a protein’s biological importance [20].
Of the 194 differentially expressed genes, 118 had been
annotated in Gene Ontology, of which 102 were included in the
HiMAP software program (19). Of those 102 genes, 52 mapped
within a single network (Fig. 3). The hubs in the network with the
highest numbers of links ($ 10) included CD44, MET, IRS1,
GRB10, ITGA2, PTGS2, and THBS1, all of which were highly
expressed in EGFR-mutant NSCLC cells, indicating that some of
the differentially expressed genes were at central positions of this
signaling network.
In light of the centrality of the PTGS2 gene in the interactome
network and the known importance of its gene product
cyclooxygenase-2 (COX-2) in the survival and metastasis of
cancer cells and its potential clinical impact given the availability
of pharmacologic tools to inhibit its enzymatic function [21], we
sought to investigate its role in EGFR-mutant NSCLC cells. We
examined whether the cyclooxygenase-2 inhibitor celecoxib
abrogated the ability of these cells to proliferate in monolayer
cultures and to form colonies in soft agar. Using celecoxib at low
doses (0.5 mM and 1.0 mM) to minimize nonspecific effects, colony
formation in soft agar decreased in a dose-dependent manner
(Fig. 4), whereas proliferation in monolayers did not change (data
not shown).
Cell Lines with EGFR Deletions and Point Mutations
Have Distinct Expression Profiles
Among patients with EGFR-mutant NSCLC, differences in
survival duration and responsiveness to EGFR TKI treatment
have been observed depending on the type of EGFR somatic
mutation (exon 21 point mutations versus exon 19 deletions)
[22;23], suggesting that these two types of somatic mutations
confer distinct biologic properties to NSCLC cells. Supporting this
possibility is evidence that these two types of somatic mutations
confer distinct biochemical properties to EGFR [9–11]. Although
hierarchical clustering did not segregate the two types of mutations
into two distinct subgroups (Fig. 1), we hypothesized that
supervised analysis would reveal transcriptional differences
between the two types of mutations. Indeed, clear transcriptional
differences were observed. Using specific criteria (P,0.01, at least
two-fold change), we identified a 270-gene signature in EGFR-
mutant cell lines (which was not present in EGFR-wild-type cell
lines) that distinguished the two types of mutations. These genes
are listed in File S5 and illustrated in a clustered heat map in Fig. 5.
We examined 7 of the 270 genes by quantitative PCR and
validated that 4 (57%) were differentially expressed between cell
lines with L858R mutations versus those with D746–750
mutations (File S6). The 270-gene signature was analyzed for
enrichment in specific gene functions as defined by the Gene
Ontology Signature Database. L858R-mutant cells were enriched
for genes in the cyclic AMP-dependent protein kinase- , protein
phosphatase-2e-, Ras-family member RAB3D-, and phospholi-
pase-Cb1-dependent pathways, whereas the D746–750 mutants
were enriched for genes in the CXC chemokine ligands (2 and 3)-,
integrin a6-, guanylate binding proteins (1, 2, and 3)-, and
interleukin-7 and 10-dependent pathways (File S7), demonstrating
that the gene sets activated by the two mutation types are
functionally distinct.
Genes Regulated by EGFR TKI Treatment
To identify gene expression changes that preceded, and possibly
contributed to, the biologic effects of EGFR TKI treatment on
EGFR-mutant NSCLC cells, the cells were subjected to short-term
treatment with gefitinib. As a negative control in this experiment,
we used the TKI-resistant H1975 cells, which have a T790M
mutation that blocks binding to the EGFR TKI [17]. Using
specific criteria (P,0.05), we found that 54 genes were regulated
by TKI exclusively in the TKI-sensitive cell lines (HCC827,
H3255, and H4006) (File S8), none of which have, to our
knowledge, been reported to be EGFR-dependent genes. Among
these genes, we examined 14 by quantitative PCR and validated
that 10 (71%) were differentially regulated in TKI-sensitive and
resistant cells (File S9). Genes that increased in response to TKI
included, among others, cell cycle regulators (CCNG2, CDKN1B,
ID2, and KNTC2) and a ligand for EphA2 (EFNA1). Genes that
decreased include the EphA2 receptor tyrosine kinase, cytokines
(LIF, CCL20, and IL17B), transcription factors (FOXD1 and
POU1F1), and protein phosphatases (DUSP4 and DUSP6).
Reciprocal Regulation of EphA2 and EFNA1 is EGFR-
Dependent
In light of the importance of the EphA axis in tumorigenesis [24;25],
we further investigated the effects of TKI treatment on the
expression of EphA2, other EphA family members, and their ligand
EFNA1. Quantitative PCR and western analysis confirmed that
gefitinib reciprocally regulated the expression of EphA2 and its
ligand EFNA1 in TKI-sensitive cell lines (HCC827, H4006, and
H3255)butnotintheTKI-resistantH1975cells(Fig.6A–C).EphA1,
EphA5, and EphA6 did not change with gefitinib treatment (Fig. 7A,
E, and F); EphA4 decreased in only a subset of TKI-sensitive cells
(H4006 but not HCC827) (Fig. 7C); and EphA3 was inhibited in an
EGFR-independent manner (indicated by the TKI-induced sup-
pressioninH1975cells)(Fig.7B).Tomorefullyevaluatewhetherthe
suppression of EphA2 expression was EGFR-mediated, we exam-
ined the effectofanother EGFRTKI,erlotinib, andfound that ittoo
inhibited EphA2 expression in TKI-sensitive cells, to an extent
similar to that of gefitinib (Fig. 7F).
NSCLC Transcriptome
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We postulated that EphA2 signaling maintains neoplastic features
of NSCLC cells and tested this hypothesis by treating HCC827
cells with EphA2-Fc, a recombinant peptide containing the EphA2
extracellular domain fused to the Fc fragment of IgG, which
prevents the interaction of ephrin A ligands with endogenous
EphA, effectively blocking EphA activation [26]. Relative to that
of controls, EphA2-Fc-treated cells exhibited decreased colony
formation in soft agar (Fig. 8) whereas their proliferation in
monolayer cultures did not change (data not shown), indicating
that EphA was required for the anchorage-independent pro-
liferation of these cells.
DISCUSSION
Here we report that NSCLC cells with somatic EGFR mutations
have a unique transcriptional profile and that cell lines with the
two most common types of EGFR mutations have clear
transcriptional differences. By mining gene expression databases
using a mutant EGFR-specific signature as a probe, we found that
many of the genes in this expression signature were EGFR-
dependent, converged into common networks on the basis of known
or predicted protein interactomes, and were expressed in tumors
from a subset of patients with NSCLC. Two genes were elucidated,
EphA2and PTGS2,thatpromotedtheclonogenicityofEGFR-mutant
NSCLC cells, which are of particular interest from a clinical
standpoint because they can be inhibited pharmacologically.
Genes within the mutant EGFR gene expression signature
encode proteins with a diverse set of cellular functions. The
influence of EGFR on this signature was demonstrated by its
overlap with that of EGFR-transfected MCF-7 cells and the
presence of known EGFR transcriptional targets, including
PTGS2, the ErbB ligands EREG and AREG, and Met, a receptor
tyrosine kinase that was recently reported to be activated in EGFR-
mutant NSCLC cells and to promote TKI resistance in these cells
[8;27–29]. Here we showed that the gene product of PTGS2,
cyclooxygenase-2, has an important role, promoting anchorage-
independent growth. This signature contained many genes not
previously known to be highly expressed in EGFR-mutant
NSCLC, including LY96 and CX3CL1, which have known
immunomodulatory functions. LY96 encodes MD2, an accessory
molecule required for the activation of toll-like receptor-4, which
promotes cell survival and induces the secretion of immunosup-
Figure 3. Interactome of genes in the mutant EGFR expression signature. Theoretical protein-protein physical and functional interaction map
(interactome) was drawn using HiMAP software. Genes from the signature are indicated in red.
doi:10.1371/journal.pone.0001226.g003
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surveillance [30]. CX3CL1 encodes a secreted protein called
fractalkine that recruits CX3CR1-expressing natural killer and T
lymphocytes to the tumor microenvironment, thereby promoting
natural killer-dependent antitumor responses in vivo [31]. On the
other hand, fractalkine has also demonstrated pro-metastatic
properties based on evidence that it promotes tumor cell migration
and enhances adhesion of tumor cells to endothelial cells [32;33].
To identify genes regulated in an EGFR-dependent manner, we
treated EGFR-mutant NSCLC cells with gefitinib. Two of the
genes identified by this approach, EphA2 and its ligand EFNA1,
were regulated in a reciprocal fashion. Potentially mediating this
effect of gefitinib, mitogen-activated protein kinase, a downstream
effector of EGFR, inhibits EFNA1 expression, thereby relieving the
EFNA1-induced suppression of EphA2 expression [25]. Moreover,
we found that EphA2/EFNA1 interactions were required for the
anchorage-independent growth of HCC827 cells, which corrobo-
rates findings from a previous study demonstrating that v-ErbB-
dependent cellular transformation is attenuated by EphA2 ligand-
binding [25]. Other genes we found to be regulated by gefitinib in
TKI-sensitive cells include CCNG2, CDKN1B, ID2, and KNTC2,
which are components of cell cycle regulatory pathways. Given
that their expression changed before any biochemical evidence of
proliferative arrest or apoptosis, these genes might be part of an
anti-proliferative signaling program activated by gefitinib. Lastly,
two of the genes that decreased in abundance with gefitinib
Figure 4. Cyclooxygenase-2 inhibition decreases NSCLC anchorage-independent growth. Representative images of colonies of NSCLC cell lines
(upper panels) were quantified (lower panels) after growing them in soft agar in the presence or absence of celecoxib. Results are the means of at
least three independent experiments.
doi:10.1371/journal.pone.0001226.g004
Figure 5. Expression signature that distinguishes two types of EGFR
mutations. A 194-gene signature present in EGFR-mutant but not
EGFR–wild-type cell lines distinguishes L858R (P.M. [point mutation])
from D746–750 (deletion). Cells were treated with (+) or without (2)
gefitinib. A partial list of the genes that are differentially expressed in
the two groups is indicated on the right.
doi:10.1371/journal.pone.0001226.g005
NSCLC Transcriptome
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EGFR-mutant cells, suggesting that these genes are potentially
important EGFR transcriptional targets in these cells.
In summary, we have identified a transcriptome in NSCLC cells
that elucidates mutant EGFR-induced gene expression changes
and provides a transcriptional basis for the biologic differences
observed in NSCLC with the two most commonly occurring types
of EGFR mutations. Further analysis of these genes may inform us
about biologic processes that can be used to identify intracellular
targets of potential therapeutic benefit for patients with this
disease.
MATERIALS AND METHODS
Reagents
Gefitinib (Astra Zeneca Pharmaceuticals, Wilmington, DE) and
erlotinib (OSI Pharmaceuticals, Melville, NY) were gifts. We
purchased a recombinant murine EphA2-Fc chimera (R&D
Systems, Minneapolis, MN), polyclonal antibodies derived in
rabbits against EphA2 and EFNA1 (Santa Cruz Biotechnologies,
Santa Cruz, CA), a horseradish peroxidase–linked anti-mouse and
ant-rabbit secondary antibodies (Cell Signaling Biotechnology,
Beverly, MA), and an antibody against b-actin (Sigma-Aldrich, St.
Louis, MO).
Cell Lines
The NSCLC cell lines used in this study were purchased from the
American Type Culture Collection (Manassas, VA) and were
grown in 5% CO2 at 37uC in RPMI 1640 medium with high
glucose (4.5 g/L; GIBCO-BRL, MD), supplemented with 10%
fetal bovine serum (Hyclone, Logan, Utah).
Gene Expression Profiling
RNAs were isolated by using the RNeasy Mini Kit (Qiagen,
Valencia, CA) and hybridized to Affimetrix U133+2.0 gene
expression chips at the M.D. Anderson Cancer Center Microarray
Core Facility (supported in part by grant CA #16672). dChip
(http://www.dchip.org) (2005 version) was used to extract expres-
sion valuesfor each probe set. Controlprobe setsand probe sets with
suffixes ‘‘_s_at’’ and ‘‘_x_at’’ on their ID were excluded (because
these probe sets may target more than one unique sequence), leaving
39,114 of 54,675 original probe sets for further analysis.
Determination of differentially expressed genes
Two-sample t tests (using log-transformed data) were used to
determine significant differences in gene expression between EGFR-
mutant and -wild-type NSCLC cell lines and between EGFR-
transfected and parental MCF-7 cells (P values were two-sided). For
Figure 6. Reciprocal regulation of EphA2 and EFNA1 in NSCLC cell lines. Quantitative PCR analysis (A, B) and western blotting (C) of EphA2 (A, C)
and EFNA1 (B, C) in cell lines treated for 6 h with (+) or without (2) gefitinib. Quantitative PCR results represent the means of at least three
independent experiments and were normalized based on expression of the housekeeping gene L32. The numbers under the bands are the results of
densitometric analysis after normalizing for loading differences based on actin.
doi:10.1371/journal.pone.0001226.g006
NSCLC Transcriptome
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calculated as the log2(gefitinib-treated/vehicle-treated).
GO enrichment analysis
Functional gene groups as defined by Gene Ontology (GO)
annotation (http://www.geneontology.org) were evaluated for
enrichment within our own experimentally-derived gene sets.
Essentially as described in [34], one-sided Fisher’s exact tests were
performed to assess whether or not genes in each GO functional
group were over-represented in our gene set (the 16,172 genes
represented by the 39,114 probe sets on the array were used as the
reference population). Gene Ontology annotations were obtained
from the NCBI’s annotation file gene2go (ftp://ftp.ncbi.nlm.nih.
gov/gene/DATA). In addition to one-sided Fisher’s exact P-values,
Q-values were computed to account for multiple term testing, using
the method by Storey et al.[ 3 5 ] .
HiMAP interactome analysis
Gene lists were imported into the HiMAP program (http://www.
himap.org/index.jsp) for protein-protein interaction network
analysis. HiMAP (19) includes both experimentally-validated
protein-protein interactions (as cataloged in the Human Protein
Reference Database, or HPRD [www.hprd.org]), and predicted
protein-protein interactions based on a probabilistic model
integrating multiple factors, including interactome data from the
Database of Interacting Proteins [36], protein domain data,
genome-wide expression data, and functional annotation data
from GO.
Analysis of the EGFR mutation gene signature in
additional profile datasets
Expression values were visualized as color maps using the Cluster
and Java TreeView programs [37; 38]. Expression values in the
human lung adenocarcinoma datasets were transformed to
standard deviations from the tumor mean. The set of profiles
analyzed in the Harvard dataset were the same set as was analyzed
in Beer et al. (15). For correlating the human NSCLC tumor
profiles with the mutant EGFR gene signature (Figure 2C), +1 and
-1 were used to represent each of the genes up and down,
respectively, in the signature. The Pearson’s correlation coefficient
was computed based on the comparison of the mutant EGFR
signature pattern to that of each human NSCLC tumor profile. In
100 separate simulation tests, a randomly generated gene signature
(with the same number of up and down genes as there was in the
mutant EGFR signature) was generated, and the Pearson’s
correlation was computed based on the comparison of this
Figure 7. EGFR TKI-induced changes in expression of EphA family members. Cells were treated for 6 h with vehicle, 1 mM gefitinib (A–E), or 1 mM
erlotinib (F). RNA was extracted and subjected to quantitative PCR. Results represent the means of at least three independent experiments and were
normalized based on L32 expression.
doi:10.1371/journal.pone.0001226.g007
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did the number of tumors with significant positive correlations
(p,0.05, two-sided) to the random pattern exceed the number
that correlated positively with the mutant EGFR signature.
The Entrez Gene identifier was used for mapping genes from
the NSCLC cell line dataset to those from the human NSCLC
tumor and MCF-7 profile datasets. Where a gene was represented
several times on a given platform, an appropriate rule was used to
select the ‘‘best’’ gene probe in a manner not biased towards
detecting patterns of concordance between datasets (for human
lung tumor datasets, the probe with the greatest variation; for
MCF-7 datasets, the probe with the greatest difference in either
direction by t test between EGFR and control). As an alternative
approach to exclude potential bias, overlap between the NSCLC
and MCF-7 data sets was examined using probes randomly
selected from the NSCLC expression arrays, which did not
qualitatively affect the results reported.
Quantitative PCR
The level of mRNA for each gene was measured with SYBR-
Green–based real-time PCR. The primers used for real-time PCR
were designed by using Primer Express (Applied Biosystems,
Foster City, CA). The primer sequences used are listed in File S10.
Each cDNA sample (7 ml) was amplified by using SYBR Green
PCR Master Mix according to the manufacturer’s instructions.
The PCR products and their dissociation curves were detected
with the 7500 Fast Real-Time PCR System (Applied Biosystems).
The level of the housekeeping gene Ribosomal gene Rpl32 (L32) in
each sample was used as an internal control.
Western Blotting
Cells were lysed with M-PER Mammalian Protein Extraction
Reagent (Pierce, Rockford, IL). Lysates were cleared by
centrifugation and protein concentrations were quantified with
1X Quick Start Bradford Dye Reagent (Bio-Rad Laboratories,
Hercules, CA) so that equal amounts of protein (40 mg) could
be resolved on 10% SDS-polyacrylamide gels. After transfer
to membranes, samples were processed and visualized with
ECL Western Blotting Reagents (Amersham Biosciences,
Piscataway, NJ). All of the Western blotting data shown in
this study are representative of at least three independent
experiments.
Figure 8. EphA2-Fc inhibits NSCLC anchorage-independent growth. Representative images of colonies of NSCLC cell lines (top) with quantification
of colonies (bottom) after growth in soft agar in the presence or absence of EphA2-Fc. Results are the means of at least three independent
experiments.
doi:10.1371/journal.pone.0001226.g008
NSCLC Transcriptome
PLoS ONE | www.plosone.org 9 November 2007 | Issue 11 | e1226Anchorage-Independent Growth Assay
Abottomlayerofagarwaspreparedin60-mmwellsbyusing3 mlof
1% low melting temperature agarose in normal growth medium.
Next, 3 ml of 0.5% low melting temperature agarose in normal
growth medium containing 1610
5 cells was added on top of the
solidified bottom layer. Every 3 days, 5 mg of EphA2-Fc dissolved in
normal growth medium was added to each plate. Colonies showing
anchorage-independent growth were counted 10–30 days later.
Cell Viability Assay
Cell viability was measured with CCK-8 (Dojindo Molecular
Technologies, Gaithersburg, MD) according to the manufacturer’s
protocol, in 96-well plates (seeding density, 5,000 cells per well) at
3 days after treatment with 5 mg/ml of EphA2-Fc or 0.5 mM and
1.0 mM of celecoxib.
SUPPORTING INFORMATION
File S1 Comparison of Gene Expression in EGFR-mutant and -
wild-type NSCLC Cells. Genes listed were increased or decreased
in EGFR-mutant NSCLC cell lines (n=4) relative to that of
EGFR wild-type cell lines (n=3).
Found at: doi:10.1371/journal.pone.0001226.s001 (0.06 MB
XLS)
File S2 Quantitative PCR Analysis of Selected Genes that were
Differentially Expressed Based on Expression Profiling of EGFR-
mutant and -wild-type NSCLC Cell Lines. Results normalized
based on L32 ribosomal RNA expression.
Found at: doi:10.1371/journal.pone.0001226.s002 (0.07 MB
DOC)
File S3 Mutant EGFR expression profile includes genes with
diverse functions. Differentially expressed genes were grouped
based on their Gene Ontology functions and represented in a pie
chart to illustrate their relative abundance.
Found at: doi:10.1371/journal.pone.0001226.s003 (0.07 MB TIF)
File S4 Mutant EGFR expression profile includes genes with
diverse functions. Differentially expressed genes are listed accord-
ing to their Gene Ontology functions.
Found at: doi:10.1371/journal.pone.0001226.s004 (0.43 MB
XLS)
File S5 Comparison of gene expression in EGFR L858R versus
del746-750 NSCLC Cells. Genes listed were increased or
decreased in EGFR L858R NSCLC cell lines (n=2) relative to
that of EGFR del746-750 cell lines (n=3).
Found at: doi:10.1371/journal.pone.0001226.s005 (0.08 MB
XLS)
File S6 Quantitative PCR analysis of selected genes that were
differentially expressed in EGFR L858R and &#xF044;746-750
NSCLC Cell Lines. Results normalized based on L32 ribosomal
RNA expression.
Found at: doi:10.1371/journal.pone.0001226.s006 (0.08 MB
DOC)
File S7 Gene Ontology terms enriched in NSCLC cell lines with
EGFR L858R and del746-750.
Found at: doi:10.1371/journal.pone.0001226.s007 (0.50 MB
XLS)
File S8 Comparison of gefitinib-induced gene expression
changes in TKI-sensitive and -resistant EGFR-mutant NSCLC
cell lines. The fold difference was calculated by log2[Gefitinib-
induced change in expression in sensitive cells (HCC827, H3255,
H4006)/resistant cells (H1975)].
Found at: doi:10.1371/journal.pone.0001226.s008 (0.03 MB
XLS)
File S9 Quantitative PCR analysis of selected genes that were
regulated by gefitinib treatment in TKI-sensitive NSCLC cells
Found at: doi:10.1371/journal.pone.0001226.s009 (0.09 MB
DOC)
File S10 Primers used for quantitative PCR
Found at: doi:10.1371/journal.pone.0001226.s001 (0.03 MB
XLS)
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